Jenburkt Pharma Share Price Target 2025, 2026, 2030, 2040, 2050
Jenburkt Pharmaceuticals Ltd., founded in 1985, is an Indian company based in Mumbai. It produces and sells medicines and healthcare products like tablets, creams, and syrups. These help treat pain, fever, infections, and diabetes. The company’s products are available in India and 13 other countries.
This blog will provide the details of Jenburkt Pharma Share Price targets as far as 25 years from now (2025 – 2050) based on its fundamentals, market position, and growth potential.
What is Jenburkt Pharmaceuticals Ltd BSE: JENBURPH?
Jenburkt is known for brands like Nervijen, Zixa, and Glucotrol. It provides medicines to doctors, hospitals, and government health centers. The company also offers herbal products like sports gels and massage oils. With over 85 brands, Jenburkt uses modern technology to ensure high-quality and affordable healthcare for everyone.
Fundamental Data
| Metric | Value |
|---|---|
| Market Cap | ₹497 Cr. |
| High / Low (52W) | ₹1,375 / ₹706 |
| Stock P/E | 15.8 |
| Industry P/E | 36.0 |
| EPS | ₹71.2 |
| Book Value | ₹357 |
| Price to Book Value | 3.15 |
| PEG Ratio | 2.86 |
| ROCE | 26.2% |
| ROE | 19.4% |
| ROE 5Yr Variance | -7.45% |
| Dividend Yield | 1.36% |
| Last Year Dividend | ₹6.75 Cr. |
| Face Value | ₹10 |
| Net Profit (FY23) | ₹31.4 Cr. |
| PBT (Annual) | ₹35.2 Cr. |
| Net Cash Flow (FY23) | ₹-1.37 Cr. |
| Debt | ₹2.12 Cr. |
| Debt to Equity | 0.01 |
| Current Assets | ₹104 Cr. |
| Current Liabilities | ₹17.7 Cr. |
| Promoter Holding | 46.7% |
| No. of Countries Served | 13 |
| No. of Brands | 85+ |
Peer Comparisions
| S.No | Company | P/E | MCap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Sales Var (%) | ROCE (%) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Torrent Pharma | 59.18 | 1,10,185 | 0.86 | 503.00 | 31.94 | 2,809.00 | 2.82 | 23.16 |
| 2 | Ajanta Pharma | 37.43 | 33,603 | 1.34 | 232.88 | 10.88 | 1,146.13 | 3.71 | 31.60 |
| 3 | Gland Pharma | 33.79 | 23,797 | 1.38 | 204.69 | 6.69 | 1,384.05 | -10.43 | 13.58 |
| 4 | ERIS Lifesciences | 57.26 | 18,858 | 0.53 | 86.93 | -17.57 | 727.45 | 49.59 | 11.27 |
| 5 | Sai Life Sciences | 182.24 | 15,089 | 0.00 | 53.85 | 35.95 | 439.78 | 14.64 | 10.57 |
| 6 | Caplin Point Labs | 28.82 | 14,839 | 0.25 | 140.07 | 18.57 | 492.96 | 13.19 | 26.46 |
| 7 | Marksans Pharma | 26.15 | 9,612 | 0.28 | 105.06 | 26.02 | 681.85 | 16.33 | 20.61 |
| 8 | Jenburkt Pharma | 15.84 | 497 | 1.36 | 6.51 | 20.56 | 36.89 | 3.45 | 26.19 |
| Period | Share Price (INR) |
|---|---|
| Before 1 Year | ₹738.95 |
| Before 6 Months | ₹1040 |
| Before 5 Years | ₹343.45 |
| All-Time Max | ₹1375 |
Jenburkt Pharma’s share price could rise tomorrow because the company has almost no debt, pays good dividends, and earns substantial profits. It produces over 85 medicine brands, exports to 13 countries, and works with over 1 lakh doctors. With a solid presence in India and growing global markets, the company looks set for steady growth in the future. The price may fluctuate tomorrow, but the long-term growth potential remains strong.
| Day | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| Tomorrow | -22 from today’s price | +40 from today’s price |
JENBURPH Indicator Based Technical Analysis
NOTE!
Signals may differ across timeframes. If you’re planning to purchase JENBURPH and keep it for more than one week, it’s suggested that you choose signals from weekly and daily timeframes. For trading in the short term, signals that range from 5 minutes to 1-hour timeframes are better appropriate.
Jenburkt Pharmaceuticals grows steadily, focusing on pain management and anti-arthritic and antibiotic products. New launches like Zixa products and EnergyGel boost growth. By 2025, Jenburkt expects higher domestic and international sales, especially in pain and diabetes products, potentially driving its share price upward significantly.
Our analysis shows that the share price is expected to be between Rs 957 and Rs 1535.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2025 | 957 | 1535 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 1105 | 1370 |
| February | 960 | 1225 |
| March | 970 | 1105 |
| April | 995 | 1235 |
| May | 1080 | 1275 |
| June | 1110 | 1305 |
| July | 1140 | 1330 |
| August | 1165 | 1350 |
| September | 1185 | 1375 |
| October | 1210 | 1400 |
| November | 1275 | 1455 |
| December | 1340 | 1535 |
In 2026, Jenburkt will expand its domestic and international markets. New wellness products like Zixa Ultra Strong Gel drive business. With 1,000+ stockists and 4 lakh+ pharmacies, Jenburkt grows revenue. Strong exports and quality medicines likely push its share price higher.
Our analysis shows that the share price is expected to be between Rs 1345 and Rs 1985.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2026 | 1345 | 1985 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 1400 | 1650 |
| February | 1350 | 1580 |
| March | 1365 | 1625 |
| April | 1425 | 1700 |
| May | 1480 | 1745 |
| June | 1505 | 1780 |
| July | 1540 | 1810 |
| August | 1580 | 1835 |
| September | 1605 | 1860 |
| October | 1640 | 1895 |
| November | 1700 | 1940 |
| December | 1765 | 1985 |
By 2030, Jenburkt will strengthen its pharmaceutical market position, targeting chronic and neurological disorders. Popular products like Nervijen and Glucotrol fuel growth. International sales and demand in emerging markets soar, likely causing significant stock appreciation due to its innovative portfolio.
Our analysis shows that the share price is expected to be between Rs 3275 and Rs 3985.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2030 | 3275 | 3985 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 3340 | 3700 |
| February | 3285 | 3580 |
| March | 3305 | 3625 |
| April | 3375 | 3735 |
| May | 3450 | 3785 |
| June | 3485 | 3820 |
| July | 3525 | 3855 |
| August | 3570 | 3895 |
| September | 3600 | 3920 |
| October | 3655 | 3965 |
| November | 3730 | 3980 |
| December | 3795 | 3985 |
In 2040, Jenburkt thrives with its pain and anti-diabetic medicines. The company advances R&D and enters digital health solutions. Its global reach and innovative wellness products boost market share, likely leading to significant long-term share price growth driven by strong fundamentals.
Our analysis shows that the share price is expected to be between Rs 6875 and Rs 7855.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2040 | 6875 | 7855 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 6950 | 7500 |
| February | 6900 | 7400 |
| March | 6930 | 7450 |
| April | 7025 | 7555 |
| May | 7120 | 7655 |
| June | 7155 | 7700 |
| July | 7200 | 7735 |
| August | 7250 | 7775 |
| September | 7300 | 7800 |
| October | 7350 | 7835 |
| November | 7450 | 7850 |
| December | 7550 | 7855 |
By 2050, Jenburkt will lead globally, targeting complex diseases. Continuous R&D and diverse products ensure growth. Strong presence in the U.S., Europe, and emerging markets expands market share. Innovative wellness products likely drive significant share price growth, making them lucrative investments.
Our analysis shows that the share price is expected to be between Rs 11,500 and Rs 12,999.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2050 | 11500 | 12999 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 11650 | 12300 |
| February | 11600 | 12150 |
| March | 11650 | 12200 |
| April | 11800 | 12450 |
| May | 11950 | 12550 |
| June | 12000 | 12600 |
| July | 12050 | 12650 |
| August | 12100 | 12700 |
| September | 12150 | 12750 |
| October | 12200 | 12800 |
| November | 12300 | 12850 |
| December | 12400 | 12999 |
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2025 | 957 | 1535 |
| 2026 | 1345 | 1985 |
| 2030 | 3275 | 3985 |
| 2040 | 6875 | 7855 |
| 2050 | 11500 | 12999 |
| Category | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|
| Promoters | 46.68% | 46.69% | 46.71% | 46.71% | 47.23% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DIIs | 0.12% | 0.12% | 0.00% | 0.00% | 0.00% |
| Public | 53.20% | 53.20% | 53.28% | 53.29% | 52.78% |
Should I Buy Jenburkt Pharma Stock?
Promoter holding in Jenburkt Pharma is gradually rising, showing they strongly believe in the company’s future. Foreign investors (FIIs) have completely sold out, while public holding remains steady. This suggests low risk. For long-term investors, buying small amounts slowly seems like a safe and smart choice.
Natco Pharma Share Price Target 2025, 2026, 2030, 2040, 2050
Jenburkt Pharma Ltd Earning Results (Financials)
| Particulars | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
| Sales (₹ Cr) | 149 | 142 | 137 | 124 | 109 | 119 |
| Expenses (₹ Cr) | 110 | 109 | 106 | 97 | 89 | 99 |
| Operating Profit | 39 | 33 | 30 | 27 | 20 | 20 |
| OPM % | 26% | 23% | 22% | 22% | 18% | 17% |
| Other Income (₹ Cr) | 6 | 5 | 5 | 5 | 4 | 4 |
| Interest (₹ Cr) | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation (₹ Cr) | 3 | 2 | 2 | 2 | 2 | 2 |
| Profit Before Tax | 42 | 35 | 33 | 30 | 22 | 21 |
| Net Profit (₹ Cr) | 31 | 26 | 25 | 22 | 16 | 15 |
| EPS (₹) | 71.17 | 58.87 | 55.76 | 48.59 | 35.95 | 32.40 |
| Tax % | — | 26% | 25% | 25% | 24% | 30% |
| Dividend Payout % | — | 26% | 26% | 25% | 28% | 25% |
Expert Forecasts on The Future of Jenburkt Pharma Ltd.
Jenburkt Pharma’s profit, sales, and EPS are growing steadily each year. Its operating margins are solid. The company also pays regular dividends. Looking ahead, growth seems likely to continue as the company is stable and performs consistently. Experts suggest it’s a strong hold for long-term investors.
Is Jenburkt Pharma Stock Good to Buy? (Bull case & Bear case)
Bullish Case:
- Consistent profit and EPS growth
- Strong ROCE & almost debt-free
- Regular dividend payout
- Expanding globally
Bearish Case:
- Slow sales growth
- Low trading volumes (liquidity risk)
- Small-cap, limited analyst coverage
Conclusion
Jenburkt Pharma maintains a strong presence in India and overseas, offering a wide range of medicines and healthcare products. The company actively serves government institutions and private pharmacies with its branded formulations. Consistently growing sales, Jenburkt Pharma expects to expand in the short and long term. If you’re considering an investment, you should read the full article for details about the company’s performance and future stock projections.
Piramal Pharma Share Price Target 2025, 2026, 2030, 2040, 2050
